Viewing nowHyundai Pregabalin Tablets 75 mg
Pregabalin 75mg
Tablet · Prescription medication
Hyundai Pharmaceutical Co., Ltd.

MFDS item code 201800511 · Approved 2018.01.29 · Insurance code 642004170
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication helps alleviate peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in epilepsy patients, regardless of secondary generalized symptoms. Additionally, it is effective in improving symptoms of fibromyalgia. It is used to relieve symptoms of various neuro-related disorders and enhance therapeutic efficacy.
The total daily dose of this medicine, pregabalin, is administered orally in 2 divided doses, with or without food. Because this medicine is primarily eliminated by the kidneys, the dose must be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg per day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased to 225 mg twice daily (450 mg per day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over a period of at least 1 week. 5. Patients with renal impairment This medicine is primarily eliminated by the kidneys as unchanged drug after entering the systemic circulation. The clearance of this medicine is directly affected by creatinine clearance; therefore, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) | Starting dose (mg/day) | Maximum dose (mg/day) | Dosing frequency ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = Divide the total daily dose into 3 doses BID = Divide the total daily dose into 2 doses QD = Administer once daily a: The total daily dose (mg/day) should be divided as indicated in the dosing frequency. b: The supplemental dose is a single additional dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so if symptoms of depression or mood changes occur during treatment, it is essential to inform your healthcare provider immediately. Patients with hypersensitivity to this medication should not take it. Diabetic patients should be cautious as weight gain may require adjustments to blood sugar control medications. If symptoms of angioedema, such as swelling of the face or around the mouth, occur, the use of this medication should be discontinued immediately. Elderly patients may be at increased risk of falls due to dizziness or drowsiness, so special caution should be exercised, especially in the early stages of treatment. Transient visual disturbances or changes in vision may occur, and these symptoms may improve upon discontinuing the medication. Abrupt discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it is advisable to taper off gradually. Patients with a history of substance abuse may be at higher risk of dependence on this medication, so caution is advised during use. Patients with impaired renal function may require adjustment of the medication dose. Patients with heart disease should be carefully monitored for potential cardiac issues, such as congestive heart failure, when using this medication. Concomitant use of this medication with opioid analgesics may increase central nervous system depressant effects, leading to risks of respiratory distress, so caution should be exercised. During early pregnancy, the risk of fetal abnormalities exists, so pregnant women should not take this medication, and women of childbearing age should use effective contraception. Breastfeeding women should consider discontinuing breastfeeding or stopping the medication, as it may be passed on through breast milk. Activities that may be dangerous, such as driving or operating machinery, should be avoided until dizziness or drowsiness has completely resolved after taking this medication. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and treatment such as hemodialysis may be necessary.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is best to maintain a storage temperature in the range of 1 to 30 degrees Celsius.
White or pale yellow round tablets
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Tablet · Prescription medication
Hyundai Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.